全文获取类型
收费全文 | 1161篇 |
免费 | 50篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 62篇 |
妇产科学 | 7篇 |
基础医学 | 103篇 |
口腔科学 | 23篇 |
临床医学 | 56篇 |
内科学 | 199篇 |
皮肤病学 | 44篇 |
神经病学 | 23篇 |
特种医学 | 50篇 |
外科学 | 170篇 |
综合类 | 285篇 |
预防医学 | 30篇 |
眼科学 | 34篇 |
药学 | 46篇 |
1篇 | |
中国医学 | 3篇 |
肿瘤学 | 74篇 |
出版年
2022年 | 7篇 |
2021年 | 16篇 |
2020年 | 16篇 |
2019年 | 13篇 |
2018年 | 20篇 |
2017年 | 16篇 |
2016年 | 12篇 |
2015年 | 30篇 |
2014年 | 33篇 |
2013年 | 36篇 |
2012年 | 55篇 |
2011年 | 47篇 |
2010年 | 72篇 |
2009年 | 65篇 |
2008年 | 84篇 |
2007年 | 77篇 |
2006年 | 72篇 |
2005年 | 42篇 |
2004年 | 63篇 |
2003年 | 26篇 |
2002年 | 41篇 |
2001年 | 36篇 |
2000年 | 25篇 |
1999年 | 24篇 |
1998年 | 30篇 |
1997年 | 33篇 |
1996年 | 29篇 |
1995年 | 21篇 |
1994年 | 21篇 |
1993年 | 9篇 |
1992年 | 17篇 |
1991年 | 15篇 |
1990年 | 8篇 |
1989年 | 8篇 |
1988年 | 11篇 |
1987年 | 6篇 |
1986年 | 9篇 |
1985年 | 7篇 |
1984年 | 9篇 |
1983年 | 2篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 3篇 |
1979年 | 5篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1976年 | 6篇 |
1971年 | 2篇 |
1967年 | 2篇 |
1953年 | 1篇 |
排序方式: 共有1214条查询结果,搜索用时 31 毫秒
151.
152.
Endothelial cell prostacyclin (PGI2) inhibits platelet activation by raising platelet cyclic AMP. Previously, platelet activation was also shown to be blocked by plasmin formed by endothelium-derived tissue plasminogen activator (TPA). We have now studied interactions between PGI2 and plasmin in the control of platelet function. PGI2 and plasmin cause synergistic inhibition of thrombin- and ADP-induced aggregation of washed platelets. Inhibition by PGI2 is similarly potentiated by TPA added to platelet-rich plasma to generate plasmin. Thrombin-stimulated rise in platelet cytosolic Ca2+, measured by fura2 fluorescence, and thromboxane A2 formation, measured by radioimmunoassay (RIA), are likewise synergistically inhibited by PGI2 and plasmin. Plasmin neither increases nor potentiates PGI2-stimulated increases in platelet cyclic AMP. Thus, PGI2 and plasmin cause synergistic inhibition of platelet activation by both cyclic AMP-dependent and independent mechanisms. This interaction between two different endothelium-derived products may play an important role in localizing the hemostatic plug to a site of vascular injury by preventing further thrombin-mediated accrual of platelets. 相似文献
153.
154.
155.
156.
157.
158.
159.
160.
Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. 总被引:4,自引:2,他引:2
van Rensburg CJ Honiball PJ Grundling HD van Zyl JH Spies SK Eloff FP Simjee AE Segal I Botha JF Cariem AK Marks IN Theron I Bethke TD 《Alimentary pharmacology & therapeutics》1996,10(3):397-401
BACKGROUND: Pantoprazole is a substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+, K+- ATPase. METHODS: Pantoprazole 40 mg and 80 mg were compared in a randomized double-blind study in 192 out-patients with stage II or III (Savary-Miller classification) reflux oesophagitis. Patients received either pantoprazole 40 mg (n = 97) or pantoprazole 80 mg (n = 95), once daily before breakfast for 4 weeks. Treatment was extended for a further 4 weeks if the oesophagitis had not healed. RESULTS: After 4 weeks complete healing of the reflux oesophagitis was seen in 78% of protocol-correct patients given pantoprazole 40 mg daily (n = 86), and in 72% in the 80 mg (n = 87) group. The cumulative healing rates after 8 weeks were 95 and 94%, respectively (P > 0.05, Cochran-Mantel- Haenszel), and time until healing of oesophagitis comparable in both groups. Differences between doses were also not significant in an intention-to-treat analysis. Both dosing schedules were well tolerated and the patients experienced remarkable symptom relief. No adverse event or changes in laboratory values of clinical significance could definitely be ascribed to the trial medication. CONCLUSION: The 40 mg pantoprazole dosage is comparable to 80 mg in reflux oesophagitis, both in efficacy and tolerability. 相似文献